Nnaemeka Ndodo
Biographic Data
| ID | 9022940 |
|---|---|
| NAME | Nnaemeka Ndodo |
| GIVEN NAMES | Nnaemeka |
| FAMILY NAME | Ndodo |
| SIGNATURE | NDODO N |
| AFFILIATIONS | Nigeria Centre for Disease Control |
| ORCID | 0000-0003-2792-8311 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Covid-19 vaccine effectiveness studies in Nigeria
The “lickety–split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days [...]
Epidemiological comparison of the first and second waves of the Covid-19 pandemic in Nigeria, February 2020–April 2021
BACKGROUND: With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. METHODS: We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis Sys…
No prominent works on this page.
Epidemiological comparison of the first and second waves of the Covid-19 pandemic in Nigeria, February 2020–April 2021
BACKGROUND: With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. METHODS: We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis Sys…
Covid-19 vaccine effectiveness studies in Nigeria
The “lickety–split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days [...]
COVID-19 epidemiological studies (2 works) · Disease (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Outbreak (2 works) · Pandemic (2 works) · Virology (2 works) · 2019-20 coronavirus outbreak (1 works) · Biology (1 works) · Case fatality rate (1 works)